Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase
journal contributionposted on 29.04.2021, 16:41 by Stephanie M. Stanford, Michael A. Diaz, Robert J. Ardecky, Jiwen Zou, Tarmo Roosild, Zachary J. Holmes, Tiffany P. Nguyen, Michael P. Hedrick, Socorro Rodiles, April Guan, Stefan Grotegut, Eugenio Santelli, Thomas D. Y. Chung, Michael R. Jackson, Nunzio Bottini, Anthony B. Pinkerton
Obesity-associated insulin resistance plays a central role in the pathogenesis of type 2 diabetes. A promising approach to decrease insulin resistance in obesity is to inhibit the protein tyrosine phosphatases that negatively regulate insulin receptor signaling. The low-molecular-weight protein tyrosine phosphatase (LMPTP) acts as a critical promoter of insulin resistance in obesity by inhibiting phosphorylation of the liver insulin receptor activation motif. Here, we report development of a novel purine-based chemical series of LMPTP inhibitors. These compounds inhibit LMPTP with an uncompetitive mechanism and are highly selective for LMPTP over other protein tyrosine phosphatases. We also report the generation of a highly orally bioavailable purine-based analogue that reverses obesity-induced diabetes in mice.
Read the peer-reviewed publication
insulin receptorobesity-induced diabetesnovel purine-based chemical seriesLMPTP inhibitorsdecrease insulin resistanceprotein tyrosine phosphatasesliver insulin receptor activation motiftype 2 diabetesbioavailable purine-based analogueLow-Molecular-Weight Protein Tyrosi...report developmentinsulin resistancelow-molecular-weight protein tyrosi...Orally Bioavailable Purine-Based In...